Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0.

× No keyword cloud information.

50 in total

Review 1. 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer.

Authors: Laura Fugazzola; Rossella Elisei; Dagmar Fuhrer; Barbara Jarzab; Sophie Leboulleux; Kate Newbold; Jan Smit
Journal: Eur Thyroid J Date: 2019-08-28

Review 2. Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors: Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal: Gland Surg Date: 2018-10

3. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy.

Authors: Luca Giovanella; Anca M Avram; Ioannis Iakovou; Jennifer Kwak; Susan A Lawson; Elizabeth Lulaj; Markus Luster; Arnoldo Piccardo; Matthias Schmidt; Mark Tulchinsky; Frederick A Verburg; Ely Wolin
Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-07 Impact factor: 9.236

Review 4. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal: Thyroid Date: 2016-01 Impact factor: 6.568

5. Radiation dose rates of differentiated thyroid cancer patients after ¹³¹I therapy.

Authors: Pingyan Jin; Huijuan Feng; Wei Ouyang; Juqing Wu; Pan Chen; Jing Wang; Yungang Sun; Jialang Xian; Liuhua Huang
Journal: Radiat Environ Biophys Date: 2018-03-10 Impact factor: 1.925

6. Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient ¹³¹I Therapy for Differentiated Thyroid Cancer.

Authors: Cristiane J Gomes-Lima; Di Wu; Pejman H Kharazi; Gauri J Khojekar; Matthew D Ringel; Richard J Vetter; Gary Bloom; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal: Thyroid Date: 2017-12 Impact factor: 6.568

7. Sialadenitis following low dose I-131 diagnostic thyroid scan with Thyrogen® (recombinant human thyroid stimulating hormone--thyrotropin alfa).

Authors: Marta E Gonzalez; Thomas Jose Eluvathingal Muttikkal; Patrice K Rehm
Journal: J Radiol Case Rep Date: 2015-06-30

8. Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.

Authors: Toshiyuki Ikeoka; Takao Ando; Misa Imaizumi; Ikuko Ueki; Toshiro Usa; Atsushi Kawakami
Journal: Endocrine Date: 2014-05 Impact factor: 3.633

9. Investigation of factors influencing radioiodine (¹³¹I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach.

Authors: Valentina Topić Vučenović; Zvezdana Rajkovača; Dijana Jelić; Dragi Stanimirović; Goran Vuleta; Branislava Miljković; Katarina Vučićević
Journal: Eur J Clin Pharmacol Date: 2018-05-13 Impact factor: 2.953

10. Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.

Authors: Savvas Frangos; Ioannis P Iakovou; Robert J Marlowe; Nicolaos Eftychiou; Loukia Patsali; Anna Vanezi; Androulla Savva; Vassilis Mpalaris; Evanthia I Giannoula
Journal: Eur J Nucl Med Mol Imaging Date: 2015-08-01 Impact factor: 9.236